| Date |
Title |
Publication |
| 05/20/1005/20/10 |
Healthcare Reform—New Path for Biosimilars, presented at a Washington Legal Foundation Webcast
View Presentation
|
Speech |
| 05/19/1005/19/10 |
May 2010 Health Care Reform Update, presented at a BioNJ Legal Breakfast Briefing, Bridgewater, NJ
View Presentation
|
Speech |
| 04/26/1004/26/10 |
The Use of Social Media in Promotion of Medical Products, presented at PLI's Health Care 2010: Managing Risks in the New Compliance and Enforcement Environment Conference, New York
View Presentation
|
Speech |
| 04/19/1004/19/10 |
Legal Issues Arising from REMS Programs, presented at the ACI REMS Conference, New York
View Presentation
|
Speech |
| 04/15/1004/15/10 |
Healthcare Reform Law: A New Regulatory Pathway for Biosimilar Biological Products
View LawFlash
|
Washington Government Relations and Public Policy LawFlash |
| 04/15/1004/15/10 |
Healthcare Reform Law: Impact on Pharmaceutical Manufacturers
View LawFlash
|
Washington Government Relations and Public Policy LawFlash |
| 09/01/09September 2009 |
The Ever-Widening Legal Morass Around Off-Label Communication, Washington Legal Foundation's Contemporary Legal Note Series, No. 63 (click here to read the article)
|
Article |
| 08/01/09August 2009 |
Regulatory Considerations and Evolving Issues Concerning REMS Programs
View Presentation
|
Speech |
| 06/18/0906/18/09 |
Life Sciences Summer Series: Drug and Device Off-Label Promotion (a Morgan Lewis Webcast)
View Presentation
|
Webcast |
| 03/25/0903/25/09 |
Regulatory and Litigation Strategies for Life Sciences Companies Post-Wyeth v. Levine, presented as a Morgan Lewis Webcast
|
Webcast |
| 03/05/0903/05/09 |
U.S. Supreme Court Ruling in Wyeth v. Levine Rejects Preemption of Failure-to-Warn Claim
View LawFlash
|
Litigation LawFlash |
| 11/03/0811/03/08 |
The Consumer Product Safety Improvement Act of 2008: Deputizing State Attorneys General and Plaintiffs’ Lawyers
View LawFlash
|
Litigation LawFlash |
| 06/19/0806/19/08 |
Regulatory and Legal Developments Concerning Clinical Trials, presented at the 2008 BIO International Convention, San Diego, CA
|
Speech |
| 02/19/0802/19/08 |
Negotiating and Living with Consent Decrees, presented at the 6th Annual Food and Drug Law Institute Enforcement and Litigation Conference, Washington, D.C.
|
Speech |
| 01/29/0801/29/08 |
State Perspectives on Existing and Future Regulations Surrounding Sales and Marketing, presented at the 5th Annual Pharmaceutical Marketing Compliance Congress, Washington, D.C.
|
Speech |
| 12/06/0712/06/07 |
Assessing and Reducing Risks Associated with Medical Information/Product Information Communications, presented at ACI's 6th Managing Legal Risks and Avoiding Conflicts of Interest in Medical Affairs Conference, Philadelphia
|
Speech |
| 06/19/0706/19/07 |
Proactive Steps Every Provider Should Take to Avoid Government Scrutiny, presented at ACI's Preparing for Government Healthcare Fraud Enforcement Conference, Washington, D.C.
|
Speech |
| 06/18/0706/18/07 |
New Risks, New Plan: Drug Safety Concerns Show Need for Sophisticated Risk Management, Legal Times, Vol. 30, No. 25
View Article
|
Article |
| 05/17/0705/17/07 |
Compliant Models for Medical Device Grants, presented at CBI's Premier West Coast Conference on Bio/Pharmaceutical and Medical Device Grants, San Francisco
|
Speech |
| 05/17/0705/17/07 |
Regulatory and Corporate Considerations in Life Sciences Industry Investments, presented at a Morgan Lewis Seminar, Palo Alto
|
Speech |
| 04/17/0704/17/07 |
The AdvaMed Code of Ethics, presented at the AdvaMed MTLI Conference: The Regulation of Advertising, Promotion, and Sales of Medical Devices, Washington, D.C.
|
Speech |
| 01/01/072007 |
Keys to Successful Interactions with Governing Bodies, Inside the Minds: Food and Drug Law Settlements and Negotiations
View Article
|
Article |
| 12/04/062006/07 |
Overview of Healthcare Fraud Investigations in the U.S., PLC Cross-border Life Sciences Handbook 2006/07
View Chapter
|
Chapter |
| 07/18/0607/18/06 |
Crossing Paths with the FDA—Regulatory Influence on the Defense of Drug and Device Products, presented at the Defense Research Institute Teleconference
|
Speech |
| 03/29/0603/29/06 |
Generic Drug Issues: Authorized Generics, presented at the Temple University School of Pharmacy FDA/Industry Conference
|
Speech |
| 03/07/0603/07/06 |
The New Medicare Act and Its Effects on Life Sciences Companies, presented to the New Jersey Technology Council Life Sciences Industry Network
|
Speech |
| 01/01/052005/06 |
Overview of Healthcare Fraud Investigations in the U.S., PLC Cross-border Life Sciences Handbook
|
Chapter |
| 08/02/04July/August 2004 |
New Medicare Act Provides New Competitive Landscape for the Pharmaceutical Industry, FDLI Update, Vol. 36
View Article
|
Article |
| 02/28/0302/28/03 |
FDA Must Clarify Drug Makers' Ability to Publicly Defend Products, Litigation Legal Foundation Legal Update, Vol. 13, No. 7
View Article
|
Article |
| 11/04/0211/04/02 |
Navigating a Pathway to FDA Approval
View Presentation
|
Speech |
| 09/06/0209/06/02 |
FTC, Not FDA, Should Regulate Online Food Information, Legal Backgrounder, Vol. 17, No. 38
|
Article |
| 08/01/0208/01/02 |
FDA Challenges to Pharmaceutical Company Control of Product Lifecycle Management, FDLI Update
View Article
|
Article |
| 08/01/02August 2002 |
Market Exclusivity: New Legal Developments and Pharmaceutical Marketing Implications, Regulatory Affairs Focus
|
Article |
| 04/23/0204/23/02 |
HIPAA: What Medical Device Firms Should Be Doing Now
View Presentation
|
Speech |
| 04/01/0204/01/02 |
Be Wary of HP Lawsuits: Emerging Firms, presented to AvaMed, Washington, D.C.
View Presentation
|
Speech |
| 03/01/02March 2002 |
Pharmaceutical Pricing: System Changes And Global Effects, Metropolitan Corporate Counsel
|
Article |
| 02/01/0202/01/02 |
Corporate Response to CPSC Challenge - Legal, Technical, and Public Relations Issues, presented at the ICPHSO 9th Annual Meeting of the ABA Product Safety Seminar, Washington, D.C.
View Presentation
|
Speech |
| 01/02/022003 |
Consumer Products Regulation (Chapter 13), Developments in Administrative Law and Regulatory Practice 2002-2003 (ABA Section on Administrative Law)
|
Chapter |
| 08/01/01August 2001 |
U.S. Pharmaceutical Pricing: System Changes and Global Effects, Life Sciences Industry Report
|
Article |
| 01/01/01January 2001 |
It's Worse Than You Think: US Regulatory Changes Require Pharmaceutical Company Attention, International Financial Law Review: Competition & Antitrust (Special IFLR Supplement)
|
Article |
| 01/01/01January 2001 |
New Proposed Policy Regarding Imposition of Reporting Requirements on Products Sold Outside of the United States
View White Paper
|
White Paper |
| 12/01/0012/01/00 |
Regulatory Litigation in the Innovator Pharmaceutical Industry, presented at the FDLI's Conference on Hatch-Waxman: Past, Present and Future, Washington, D.C.
View Presentation
|
Speech |
| 11/01/00November 2000 |
California Trial Court Finds Ford Acted Fraudulently by Not Reporting Safety Information to Federal Agenices
View White Paper
|
White Paper |
| 09/04/0009/04/00 |
Expect Big Change in Drug Pricing System, The National Law Journal
View Article
|
Article |
| 06/01/00June 2000 |
Providing Off-Label Use Information: New Decision Sends Industry One-Half Step Back, Regulatory Affairs Focus
|
Article |
| 02/01/0002/01/00 |
CPSC 15(b) Reporting Requirements: A Practical Guide to Knowing When and What to Report, presented to the American Bar Association, Orlando, FL
|
Speech |
| 11/08/9911/08/99 |
Marketing Your Product as a Drug or Dietary Supplement: Legal Risks and Benefits: Outline Presentation, The German-American Chamber of Commerce, Inc. and The Association of the German Pharmaceutical Industry Conference on the Regulatory Framework for OTC Drugs and Dietary Supplements, Washington, D.C.
View Presentation
|
Speech |
| 06/29/9906/29/99 |
Medical Device Update, presented to the Food and Drug Law Institute, Washington, D.C.
|
Speech |
| 12/07/9812/07/98 |
Strategies for Obtaining Market Exclusivity for Genetic Discoveries: Patent, FDA, and Contract Mechanisms, Decision Resources, Inc.
|
Article |
| 01/01/98January 1998 |
FDA Takes Important Step Toward Liberalizing Its Direct-to-Consumer Broadcast Advertising Policy, Food, Drug, Cosmetic and Medical Device Law Digest, Vol. 15, No. 1
|
Article |
| 11/01/97November 1997 |
New FDA Regulations Implementing the Dietary Supplement Health and Education Act of 1994, Legal Mind, Vol. 164, Japan
|
Article |
| 05/22/9705/22/97 |
Voluntary Standards for Consumer Products - An Antitrust Checklist, presented to the American Bar Association, Section of Administrative Law and Regulatory Practice, Washington, D.C.
|
Speech |
| 11/01/96November 1996 |
U.S. Product Liability and Preemption Under the Medical Device Amendments: The Business Implications of the Supreme Court's Medtronic Decision, Legal Mind, Vol. 152, Japan
|
Article |
| 09/17/9609/17/96 |
Regrouping and Responding After a Failed New Drug Pre-Approval Inspection by the FDA, presented at the Conference for the Institute for International Research, Philadelphia
|
Speech |
| 08/01/9608/01/96 |
Product Liability and Preemption Under the Medical Device Amendments: The Business Implications of Medtronic, Inc. v. Lohr
View White Paper
|
White Paper |
| 01/01/961996 |
Recalls of Consumer Products in U.S. Distribution, Product Safety (First Edition) (London)
|
Article |
| 04/01/94April 1994 |
Legal Considerations in Agreements for Manufacturing and Distribution of Biotechnology Products, Legal Mind (Japan), Vol. 121
|
Article |
| 03/01/9403/01/94 |
Reinvigorated Regulation of Consumer Product Safety Commission Expected with Confirmation of New Chair: ML&B White Paper
View Morgan Lewis Title
|
White Paper |
| 02/13/9402/13/94 |
The Relationship Between Product Tampering and Product Liability, presented at Closure Manufacturers Association Annual Meeting, Washington, D.C.
|
Speech |
| 11/08/9311/08/93 |
Checklist of Legal Considerations in Agreements for Manufacturing and Distribution of Biotechnology Products, presented at the Biotechnology and Business Conference, Prague, Czech Republic
|
Speech |
| 09/01/93September 1993 |
The Admissibility of 'Junk Science' Evidence: Regulatory Effects, Regulatory Affairs Professionals Society News
View Article
|
Article |
| 09/01/9209/01/92 |
New Federal Reporting Regulations for Consumer Products: ML&B White Paper
View Morgan Lewis Title
|
White Paper |
| 11/01/9111/01/91 |
Consumer Product Defects -- New Federal Reporting Obligations Concerning Product Liability Lawsuits and Injuries Caused By Consumer Products: ML&B White Paper
View Morgan Lewis Title
|
White Paper |
| 01/01/9101/01/91 |
New Federal Reporting Obligations Concerning Defects in Consumer Products: ML&B White Paper
View Morgan Lewis Title
|
White Paper |
| 06/01/90June 1990 |
U.S. Product Liability Considerations For Exposure To Pesticides From Food, Legal Mind (Japan), Vol. 76
|
Article |